These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 33125196)

  • 1. Adalimumab in the treatment of non-infectious uveitis.
    Burek-Michalska A; Turno-Kręcicka A
    Adv Clin Exp Med; 2020 Oct; 29(10):1231-1236. PubMed ID: 33125196
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adalimumab for the treatment of uveitis.
    LaMattina KC; Goldstein DA
    Expert Rev Clin Immunol; 2017 Mar; 13(3):181-188. PubMed ID: 28140700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effectiveness of adalimumab treatment for non-infectious uveitis.
    Hasegawa E; Takeda A; Yawata N; Sonoda KH
    Immunol Med; 2019 Jun; 42(2):79-83. PubMed ID: 31315546
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Challenges for further successful development of tumor necrosis factor targeting therapies for uveitis.
    Thng ZX; Regenold J; Bromeo AJ; Akhavanrezayat A; Than NTT; Khatri A; Mohammadi SS; Tran ANT; Shin YU; Karaca I; Ghoraba HH; Or CCM; Nguyen QD
    Expert Opin Investig Drugs; 2024 Feb; 33(2):95-104. PubMed ID: 38299551
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Miliary tuberculosis developing during adalimumab treatment for Behçet's disease with uveitis.
    Kim MJ; Jones N; Steeples LR
    BMJ Case Rep; 2018 Dec; 11(1):. PubMed ID: 30567192
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lower Relapses Rate With Infliximab Versus Adalimumab in Sight-Threatening Uveitis: A Multicenter Study of 330 Patients.
    Maalouf G; Andrillon A; Leclercq M; Sève P; Bielefeld P; Gueudry J; Sené T; Titah C; Moulinet T; Rouvière B; Sène D; Desbois AC; Domont F; Touhami S; Thibault T; Chamieh CE; Cacoub P; Kodjikian L; Biard L; Bodaghi B; Saadoun D
    Am J Ophthalmol; 2022 Jun; 238():173-180. PubMed ID: 35172172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biologics for the treatment of noninfectious uveitis: current concepts and emerging therapeutics.
    Thomas AS
    Curr Opin Ophthalmol; 2019 May; 30(3):138-150. PubMed ID: 30844945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biotherapies in Uveitis.
    Leclercq M; Desbois AC; Domont F; Maalouf G; Touhami S; Cacoub P; Bodaghi B; Saadoun D
    J Clin Med; 2020 Nov; 9(11):. PubMed ID: 33171664
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial.
    Nguyen QD; Merrill PT; Jaffe GJ; Dick AD; Kurup SK; Sheppard J; Schlaen A; Pavesio C; Cimino L; Van Calster J; Camez AA; Kwatra NV; Song AP; Kron M; Tari S; Brézin AP
    Lancet; 2016 Sep; 388(10050):1183-92. PubMed ID: 27542302
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Profile of adalimumab and its potential in the treatment of uveitis.
    Balevic SJ; Rabinovich CE
    Drug Des Devel Ther; 2016; 10():2997-3003. PubMed ID: 27698552
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-TNF-α therapy in refractory uveitis associated with sarcoidosis: Multicenter study of 17 patients.
    Riancho-Zarrabeitia L; Calvo-Río V; Blanco R; Mesquida M; Adan AM; Herreras JM; Aparicio Á; Peiteado-Lopez D; Cordero-Coma M; García Serrano JL; Ortego-Centeno N; Maíz O; Blanco A; Sánchez-Bursón J; González-Suárez S; Fonollosa A; Santos-Gómez M; González-Vela C; Loricera J; Pina T; González-Gay MA
    Semin Arthritis Rheum; 2015 Dec; 45(3):361-8. PubMed ID: 26092330
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of anti-tumor necrosis factor alpha agents on the outcome in pediatric uveitis of diverse etiologies.
    Deitch I; Amer R; Tomkins-Netzer O; Habot-Wilner Z; Friling R; Neumann R; Kramer M
    Graefes Arch Clin Exp Ophthalmol; 2018 Apr; 256(4):801-808. PubMed ID: 29455252
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adalimumab in Elderly Patients with Non-Infectious Uveitis. Safety and Efficacy.
    Moll-Udina A; Miguel Escuder L; Hernanz I; Llorenç V; Fonollosa A; Cordero Coma M; Sainz de la Maza M; Espinosa G; González Guijarro JJ; Lopez Lopez F; Alba-Linero C; Hernández M; Martínez Costa L; Celdrán Vivancos D; Giralt L; Artaraz J; Soler Bartrina P; Jódar Márquez M; García de Vicuña R; Esquinas C; Adán A
    Ocul Immunol Inflamm; 2021 Nov; 29(7-8):1591-1598. PubMed ID: 32657649
    [No Abstract]   [Full Text] [Related]  

  • 14. Safety of systemic therapy for noninfectious uveitis.
    Ormaechea MS; Hassan M; Onghanseng N; Park JH; Mahajan S; Al-Kirwi KY; Uludag G; Halim MS; Schlaen A; Sepah YJ; Do DV; Nguyen QD
    Expert Opin Drug Saf; 2019 Dec; 18(12):1219-1235. PubMed ID: 31801415
    [No Abstract]   [Full Text] [Related]  

  • 15. Efficacy and safety of intravitreal anti-tumour necrosis factor drugs in adults with non-infectious uveitis - a systematic review.
    Leal I; Rodrigues FB; Sousa DC; Romão VC; Duarte GS; Carreño E; Dick AD; Marques-Neves C; Costa J; Fonseca JE
    Acta Ophthalmol; 2018 Sep; 96(6):e665-e675. PubMed ID: 29577629
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Research update of anti-TNF-α biologic agents in the treatment of uveitis].
    Fan F; Zhou M; Luo Y
    Zhonghua Yan Ke Za Zhi; 2013 Mar; 49(3):285-8. PubMed ID: 23866712
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of immunomodulators in non-infectious uveitis: lights and shadows.
    Bernal-Morales C; Ramanan AV; Pavesio C
    Eye (Lond); 2024 Dec; 38(17):3231-3242. PubMed ID: 39160332
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adalimumab: A Review in Non-Infectious Non-Anterior Uveitis.
    Hoy SM
    BioDrugs; 2017 Apr; 31(2):135-142. PubMed ID: 28229433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders.
    Levy-Clarke G; Jabs DA; Read RW; Rosenbaum JT; Vitale A; Van Gelder RN
    Ophthalmology; 2014 Mar; 121(3):785-96.e3. PubMed ID: 24359625
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progress in the understanding and utilization of biologic response modifiers in the treatment of uveitis.
    Maleki A; Meese H; Sahawneh H; Foster CS
    Expert Rev Clin Immunol; 2016 Jul; 12(7):775-86. PubMed ID: 26972783
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.